Evaluation de la sécurité d’emploi des médicaments modulant les androgènes dans les maladies prostatiques, une approche pharmaco-épidémiologique

Evaluation de la sécurité d’emploi des médicaments modulant les androgènes dans les maladies prostatiques, une approche pharmaco-épidémiologique

Contexte : En France, le cancer de la prostate est une maladie fréquente de l’homme âgé et la première cause de cancer. Il est associé à une survie de 70 % à 10 ans. Différentes options thérapeutiques sont recommandées dans la prise en charge de ce cancer, parmi lesquelles l’hormonothérapie (ou thér...

Full description

Bibliographic Details
Main Author:	Scailteux, Lucie-Marie
Other Authors:	Rennes 1
Language:	fr
Published:	2017
Subjects:	Base de données médico-Administratives Cancer de la prostate Risque cardiovasculaire Thérapie par déprivation d'androgènes Population based-Study Prostate cancer Cardiovascular risk Androgen deprivation therapy
Online Access:	http://www.theses.fr/2017REN1B006

Similar Items

Intermittent androgen deprivation therapy: recommendations to improve the management of patients with prostate cancer following the GRADE approach
by: Bonfill X, et al.
Published: (2018-08-01)

Androgen deprivation therapy and the risk of subsequent keratitis
by: Dai-Wei Liu, et al.
Published: (2021-01-01)

A Comprehensive Review of Androgen Deprivation Therapy and Immunotherapy on Prostate Cancer
by: ZHU Hui, et al.
Published: (2019-10-01)

Adverse effects of androgen deprivation therapy in prostate cancer: Current management issues
by: Aditya Bagrodia, et al.
Published: (2009-01-01)

No increased risk of psoriasis in patients receiving androgen deprivation therapy for prostate cancer: a 17-year population-based study
by: Liu JM, et al.
Published: (2018-09-01)

Current Status and Future Perspectives of Androgen Receptor Inhibition Therapy for Prostate Cancer: A Comprehensive Review
by: Tae Jin Kim, et al.
Published: (2021-03-01)

Successive xanthogranulomatous prostatitis after complete remission of metastatic prostate adenocarcinoma: An extremely rare case report with review of literatures
by: Che-Hsueh Yang, et al.
Published: (2020-07-01)

Crosstalk Between AR and Wnt Signaling Promotes Castration-Resistant Prostate Cancer Growth
by: Luo J, et al.
Published: (2020-09-01)

Emerging potential of parenteral estrogen as androgen deprivation therapy for prostate cancer
by: Syed Imran Ali Shah
Published: (2015-01-01)

Risk of ischemic stroke in patients with prostate cancer receiving androgen deprivation therapy in Taiwan
by: Kuang-Ming Liao, et al.
Published: (2019-12-01)

Cardiometabolic and Skeletal Risk Factors in Black Men with Prostate Cancer Starting Androgen Deprivation Therapy
by: Orvar Gunnarsson, et al.
Published: (2015-04-01)

Endocrine manipulations in cancer prostate: A review
by: Rajesh Rajput, et al.
Published: (2012-01-01)

Dramatic mixed response of lymphangitic pulmonary metastases in newly diagnosed prostate cancer
by: Elan Gorshein, et al.
Published: (2017-01-01)

Clinical outcome and toxicity evaluation of simultaneous integrated boost pelvic IMRT/VMAT at different dose levels combined with androgen deprivation therapy in prostate cancer patients
by: Daoud MA, et al.
Published: (2017-10-01)

Autophagy in Prostate Cancer and Androgen Suppression Therapy
by: Claudia Giampietri, et al.
Published: (2013-06-01)

Serum testosterone level predicts the effective time of androgen deprivation therapy in metastatic prostate cancer patients
by: Yue Wang, et al.
Published: (2017-01-01)

Protocol for a feasibility and early efficacy study of the Comprehensive Lifestyle Improvement Program for Prostate Cancer-2 (CLIPP2)
by: A.M. Algotar, et al.
Published: (2021-03-01)

Novel Strategies for Treating Castration-Resistant Prostate Cancer
by: David Ka-Wai Leung, et al.
Published: (2021-03-01)

A Review of the Pathophysiological Mechanisms Underlying Castration-resistant Prostate Cancer
by: Crowley F, et al.
Published: (2021-06-01)

Should We Reconsider the Necessity of a Refinement of Prostate Cancer Risk Classification and Radiotherapy Treatment Strategy? Experiences from a Retrospective Analysis of Data from a Single Institution
by: Viktória Temesfői, et al.
Published: (2021-12-01)

Safety and efficacy of abiraterone acetate in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: an Italian multicenter “real life” study
by: Luca Cindolo, et al.
Published: (2017-11-01)

Testosterone therapy in men with prostate cancer: literature review, clinical experience, and recommendations
by: Abraham Morgentaler, et al.
Published: (2015-04-01)

The Role of Cytoreductive Radical Prostatectomy in the Treatment of Newly Diagnosed Low-volume Metastatic Prostate Cancer. Results from the Local Treatment of Metastatic Prostate Cancer (LoMP) Registry
by: Nicolaas Lumen, et al.
Published: (2021-07-01)

Resistance to Antiandrogens in Prostate Cancer: Is It Inevitable, Intrinsic or Induced?
by: Norman J. Maitland
Published: (2021-01-01)

Hormonal Therapies for Patients with Advanced Prostate Cancer
by: Cora N. Sternberg, et al.
Published: (2016-01-01)

The Influence of Androgen Deprivation Therapy on Prostate Size and Voiding Symptoms in Prostate Cancer Patients in Korea
by: Hoon Choi, et al.
Published: (2016-12-01)

Intermittent androgen deprivation therapy in patients with prostate cancer: Connecting the dots
by: Per-Anders Abrahamsson
Published: (2017-10-01)

AZGP1 Protein Expression in Hormone-Naïve Advanced Prostate Cancer Treated with Primary Androgen Deprivation Therapy
by: Mads Dochedahl Winther, et al.
Published: (2020-07-01)

Potential Risk of Other-Cause Mortality Due to Long-Term Androgen Deprivation Therapy in Elderly Patients with Clinically Localized Prostate Cancer Treated with Radiotherapy—A Confirmation Study
by: Hideya Yamazaki, et al.
Published: (2020-07-01)

Identification of the Transcription Factor Relationships Associated with Androgen Deprivation Therapy Response and Metastatic Progression in Prostate Cancer
by: Nitya V. Sharma, et al.
Published: (2018-10-01)

Background factors and short-term health-related quality of life in patients who initially underwent radical prostatectomy or androgen deprivation therapy for localized prostate cancer in a Japanese prospective observational study (J-CaP Innovative Study-1)
by: Satoru Ueno, et al.
Published: (2018-03-01)

Impact of androgen-deprivation therapy on the outcome of dose-escalation prostate cancer radiotherapy without elective pelvic irradiation
by: Wei-Hsien Hou, et al.
Published: (2017-01-01)

Prognostic significance of genetic polymorphisms in disease progression and survival in prostate cancer after androgen deprivation therapy
by: Tsung-Yi Huang, et al.
Published: (2015-06-01)

Efficacy and safety of degarelix in Korean patients with prostate cancer requiring androgen deprivation therapy: Open-label multicenter phase III study
by: Dalsan You, et al.
Published: (2015-03-01)

Polymorphisms of matrix metalloproteinases and their association with metastasis and the efficacy of androgen-deprivation therapy for prostate cancer in Taiwanese men
by: Cheng-Chia Lin, et al.
Published: (2015-12-01)

COMBINED RADIATION THERAPY FOR PROSTATE CANCER WITH DOSE ESCALATION BRACHYTHERAPY AND ANDROGEN DEPRIVATION
by: Auchynikau V. A., et al.
Published: (2018-09-01)

SBRT: An opportunity to improve quality of life for oligometastatic prostate cancer?
by: Gregory eAzzam, et al.
Published: (2015-05-01)

Outcomes and Prediction Models for Exclusive Prostate Bed Salvage Radiotherapy among Patients with Biochemical Recurrence after Radical Prostatectomy
by: Chi-Shin Tseng, et al.
Published: (2021-05-01)

Oligometastatic Prostate Cancer: A Comparison between Multimodality Treatment vs. Androgen Deprivation Therapy Alone
by: Bianchi, R., et al.
Published: (2022)

Factors associated with testosterone recovery after androgen deprivation therapy in patients with prostate cancer
by: Wook Nam, et al.
Published: (2018-01-01)